Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Cash flows from operating activities:
Net loss	$ (5,313)	$ (20,801)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization expense	2,007	84
Amortization of debt issuance costs	0	164
Loss on dissenting shareholders' liability	1,103	0
Gain on sale of assets	(29)	89
Share-based compensation	473	44
Impairment of operating lease right-of-use assets	56	0
Deferred income taxes	63	0
Provision for credit losses	2	0
Amortization of operating lease right-of-use assets	109	59
Gain on lease settlement	(14)	0
Changes in operating assets and liabilities, net of acquisition:
Accounts receivable	5	0
Materials and supplies	(431)	0
Prepaid expenses and other assets	124	54
Accounts payable, accrued expenses, and other liabilities	441	(509)
Operating lease liabilities	(143)	(46)
Income taxes receivable	0	44
Other assets	(375)	0
Cash provided by (used in) operating activities from discontinued operations	22	22,645
Net cash (used in) provided by operating activities	(1,900)	1,827
Cash flows from investing activities:
Cash paid for acquisition of Amplex	(18,143)	(300)
Payments for property, plant, and equipment	(8,416)	0
Proceeds from the disposal of property, plant, and equipment	95	13
Net cash provided by investing activities from discontinued operations	39,012	46,114
Net cash provided by investing activities	12,548	45,801
Cash flows from financing activities:
Proceeds from RUS Loan	615	0
Proceeds from Bank Equipment Financing Loans	248	0
Payment on Bank Loans	(35)	0
Repurchase of dissenting shares	(5,629)	0
Cash used in financing activities from discontinued operations	0	(29,100)
Net cash used in financing activities	(4,801)	(29,100)
Net increase in cash and cash equivalents	5,847	18,528
Cash, cash equivalents and restricted cash at beginning of period	18,982	454
Cash, cash equivalents and restricted cash at end of period	24,829	18,982
Total cash, cash equivalents and restricted cash at end of period	24,829	18,982
Reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets to the total amounts reported on the condensed consolidated statements of cash flows:
Cash and cash equivalents at beginning of period	18,982	454
Restricted cash included in Prepaid expenses and other assets at beginning of period	0	0
Total cash, cash equivalents and restricted cash at beginning of period	24,829	18,982
Cash and cash equivalents at end of period	24,516	18,982
Restricted cash included in Prepaid expenses and other assets at end of period	313	0
Total cash, cash equivalents and restricted cash at end of period	24,829	18,982
Supplemental disclosure of cash flow information:
Interest paid	47	997
Supplemental schedule of noncash investing and financing activities:
Purchase of property, plant, and equipment included in accounts payable	403	0
Conversion of term loan advances into additional equity of controlled entity (Amplex)	754	0
Additional investments in controlled entity (Amplex)	$ 7,500	$ 0